ICMJE DISCLOSURE FORM

Date:21 st March 2023
Your Name:Cornelius Engelmann
Manuscript Title:_ Clinical practice guidelines for acute-on-chronic liver failure: are we ready for reaching global
consensus?
Manuscript number (if known): HBSN-23-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past EU-Horizon 2020, Else- Kroener Fresenius, Albireo	36 months
3	Royalties or licenses	Hepyx Ltd.	
4	Consulting fees	Albireo	

		1	
5	Payment or honoraria for	Albireo, Novartis,	
	lectures, presentations,	Intercept/Advanz Pharma	
	speakers bureaus,		
	manuscript writing or		
	educational events		
	Payment for expert	None	
	testimony		
	Support for attending	None	
		None	
	meetings and/or travel		
	Patents planned, issued or	None	
	pending		
	i		
		<u> </u>	
	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
.0	Leadership or fiduciary role	None	
.U		NOTIC	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
1	Stock or stock options	None	
_	Stock of Stock options	140110	
2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
.3	Other financial or non-	None	
3		None	
	financial interests		
lea	se summarize the above co	onflict of interest in the foll	owing box:
lea	se place an "X" next to the	following statement to ind	licate your agreement:
	I certify that I have answer	red every question and hav	e not altered the wording of any of the questions on
	IOIIII.		

ICMJE DISCLOSURE FORM

Date: March 2023	3 21st
Your Name: Thom	as Berg
Manuscript Title: Clinica	Il practice guidelines for acute-on-chronic liver failure: are we ready for reaching global
consensus?	
Manuscript number (if l	known): HBSN-23-6

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past Abbvie, BMS, Gilead, MSD/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, Sequana Medical.	36 months Institution
3	Royalties or licenses	None	

4	Consulting fees	Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi	To me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Abbvie, Alexion, Bayer, Gilead, Eisai, Falk Foundation, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI.	To me
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Gilead, Abbvie, Intercept, Janssen	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Please place an "X" next to the following statement to indicate your agreement:
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.